Amoxicillin

Founded in 1986 by Mr. P. V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and anti-biotics, among others.

Kopran Ltd is a globally operating pharmaceutical company focused on marketing and production. The company possesses two WHO GMP approved manufacturing facilities. Their FDF facility in Khopoli is accredited by TGA, MHRA, and MCC, while their API facility in Mahad holds WHO GMP accreditation. Kopran Ltd exports its products to prominent markets in Europe, Southeast Asia, and Latin America. The company offers a diverse range of Active Pharmaceutical Ingredients (APIs) in categories such as Anti-hypertensive, Macrolides, Neuromodulator, Cephalosporins, Carbapenems, and Oncology, as well as Finished Dosage Forms in Carbapenems, Gastroenterology, Anthelmintics, Central Nervous System, Pain management, Anti-allergies, Anti-asthmatics, Anti-Infectives, Penicillins, Cardiovascular, Antiprotozoal, Oncology, Anti-Diabetics, Erectile Dysfunction, and Macrolides.

CordenPharma International, an all-encompassing CDMO for the worldwide market. Established as the global pharmaceutical service & production platform of International Chemical Investors Group in 2006, CordenPharma serves as your all-encompassing ally in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. With an expanding network of cGMP facilities throughout Europe and the US structured under five Technology Platforms – Peptides, Lipids & Carbohydrates - Highly Potent & Oncology - Injectables - Small Molecules - Antibiotics – CordenPharma specialists interpret intricate processes, concepts and ventures at any phase.

ACS DOBFAR, an Italian firm established in 1973, is a privately owned business that serves as a fully integrated producer of Cephalosporin and Penicillin APIs as well as Finished Dosage Formulations. With manufacturing facilities located across the globe routinely examined by the US FDA, it stands as a prominent company among suppliers to the US market.

CSPC Pharmaceutical Group Limited ("CSPC") (Stock code: 1093.HK) is a leading pharmaceutical group in China. The Company has been listed on the Main Board of the Hong Kong Stock Exchange since 1994 and became a constituent stock of the Hang Sang Index in 2018 (the 1st constituent stock in the pharmaceutical sector since launch of the index). CSPC is currently also a constituent stock of the "Hang Seng Composite Index", "Hang Seng Healthcare Index", "Hang Seng SCHK Mainland China Healthcare Index", "Hang Seng Stock Connect Hong Kong Index", "Hang Seng China (Hong Kong-listed) 100 Index" and "Hang Seng China Enterprises Index". CSPC mainly owns two business segments of finished drugs and bulk drugs, with innovative drugs as the core development strategy. CSPC currently has a strong product portfolio in the therapeutic areas of nervous system disease, oncology, anti-infective and cardiovascular disease. Of which "NBP", "Domeisu", "Jinyouli", "Keaili" and "Xuanning" are the most popular innovative drug products in China. Bulk drug products include vitamin C, antibiotics and caffeine series. The manufacturing facilities of CSPC are mainly located in Shijiazhuang City, Hebei Province, China. CSPC has a international R&D team with R&D bases in Shijiazhuang, Shanghai, Beijing and the United States, focusing on the discovery, research and development of small molecule targeted drugs, nano-drugs, monoclonal antibody drugs, bispecific antibody drugs, antibody-drug conjugates and biological drugs in the immune field.

Greetings, we are Sandoz B2B. As a division of Sandoz, we are completely dedicated to ensuring availability of cost-effective medication for everyone. We distribute high-quality medication globally through close collaboration with pharmaceutical partners. Whether it involves active pharmaceutical ingredients, finished dosage products, or comprehensive end-to-end CDMO solutions, we are here for you.

UNIPEX, your Intelligent and Strategic associate for pharmaceutical sectors. UNIPEX proficiency lies in the delivery of ground-breaking APIs, additives, synthesis intermediates. UNIPEX provides distinctive services in close collaboration with its principals: specialized support in R&D formulation, regulatory registration, technical workshops, and tailored solutions in Benelux. DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP Unipex

Sinopharm, a significant healthcare organization affiliated with the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, operates with a workforce of 128,000 and a comprehensive industry presence encompassing research and development, production, supply chain management, retail outlets, medical services, engineering, events, international trade, and financial services. It possesses more than 1,100 subsidiaries and 6 publicly traded companies, including Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., and China National Accord Medicines Corporation Ltd.

Daewoong Bio Inc., a standalone affiliate of the Daewoong Group located in Seoul, South Korea, was established in 1983. Daewoong Bio manufactures world-class products that comply with cGMP standards under quality assurance systems. As a primary producer, Daewoong Bio supplies APIs for worldwide distribution and multinational enterprises developing innovative products. Daewoong Bio is also a comprehensive pharmaceutical company that employs its internal research and development, production facilities, and experienced marketing team along with external global connections. Daewoong Bio specializes in the production of top-notch antibiotic APIs and general APIs.

Zhuhai United has been ratedas "backbone enterprise inthe strategic emerging industriesof Guangdong Province" for many years in a row, and honored as one of the "Top 10 Export Enterprises of APIs in China", the "Best Enterprise of Medicine R&D Production Line in China" and with many other titles. Ranking the 21st among the top 100 enterprises of Chinese pharmaceutical industry and the 35th among the top 100 healthcare product import and export enterprises in China, it is also a "Pioneering Chinese Pharmaceutical Enterprise in Preparation Internationalization" and the "Most Popular 10 Listed Pharmaceutical Companies".

Prominent provider of pharmaceutical components, drugstore apparatus, and specialized medicines. Focused on catering to the compounding market in the United States, Letco presents a diverse range of reliable and high-quality chemicals, compounding materials, and apparatus at exceptionally competitive rates. Additionally, Letco offers various enhanced solutions, such as Professional Services support and guaranteed delivery within two days, establishing Letco as the favored supplier for budget-conscious compounding pharmacies. Serving as your reliable ally, Letco is dedicated to delivering the essential resources that customers require to tackle both current and future obstacles.

We are the primary manufacturer of Avermectin worldwide and the leading producer of Ivermectin in Asia, with an annual production that constitutes half of the total in China. Additionally, we hold the top position as the producer for Tiamulin, Eprinomectin, and Emamectin Benzoate in China.

Established in 1964 in Hong Kong, The United Laboratories Co Ltd is involved in the research and development, manufacturing, and sale of its products. TUL, a company listed in Hong Kong, operates six production bases with vertically integrated production. Its product range includes semi-synthetic penicillins, cephalosporins, β-lactamase inhibitor and blends, β-lactamase intermediates, APIs, and finished products.

DPB group of enterprises, DPB Antibiotics was founded in 2005 with the objective of providing the expanding pharmaceutical sector with high-quality API’s. Leveraging extensive experience and industry insights, we are well-equipped to meet the industry’s demands. Our specialization lies in the supply of pharmaceutical APIs, Excipients & FDF. Our headquarters are located in Mumbai, India, with branch offices in China. DPB has achieved significant success by supplying to over 1200 customers within India and more than 300 customers across 40 countries in the international market. We have strong ties with many Indian manufacturers for API supplies, in addition to imports from various countries. The company's exceptional management and customer relationships have driven our turnover to $125 million. We proudly hold the title of the largest manufacturer & exporter of Isoxazoles group of APIs in the world, with the capacity to produce approximately 800 MT per annum. Furthermore, we possess the largest installed capacity in the country to manufacture high-quality oral enzymatic antibiotic APIs, with an annual capacity of around 1400 MT. DPB group has plans to increase this capacity to about 2000 MT per annum. Our plant complies with regulatory USFDA/EU-GMP guidelines. Moreover, we are the sole manufacturer of the key antibiotic Amoxicillin - Potassium Clavulanate Sterile (5:1 Mixture) with proprietary technology in India. We are also aiming to fully utilize the 180 MT per annum capacity by adding high-value products like meropenam sterile. The quality of our API sets our company apart, making it a unique brand in the industry.

Established in 1979, BMP has emerged as a reputable and foremost provider of high-grade raw materials for the pharmaceutical (human & veterinary) and health food sectors. The company offers intelligent, adaptable solutions and expert implementation in compliance with current pharmaceutical regulations, positioning B.M.P. as a dependable and credible partner in every supply chain.

With over 35 years of experience, Lark Laboratories (India) Limited has built a strong reputation for trust and reliability in the pharmaceutical formulations manufacturing industry. Established in 1979, it is rapidly emerging as a leading pharmaceutical manufacturing company in India, dedicated to providing high-quality products for better health at affordable prices worldwide. Through strategic research, expertise in manufacturing, and industry knowledge, Lark Laboratories is positioning itself as a prestigious and reputable pharmaceutical formulations manufacturer.

YSPSAH functions as a pharmaceutical corporation that is publicly traded in Malaysia, boasting a strong presence both domestically and regionally. The company specializes in a broad array of top-notch products for the market, encompassing human pharmaceuticals, over-the-counter (OTC) items, traditional and complementary medicines (TCM), functional food, and animal health products